In HER2+ breast cancer with neoadjuvant treatment, there are other putative prognostic factors not included in this analysis (tumor-infiltrating lymphocytes, PI3KCA mutation), which may influence the result of prognostic factor evaluation. Here, ERBB2 is linked to breast carcinoma.